For UK pharmaceutical and life sciences leaders
Clinicians say your technology is interesting, and then carry on as before
Interest is not adoption. The gap between clinical curiosity and sustained practice change is where most MedTech commercial plans quietly fail, and it rarely closes without deliberate intervention.
Two minutes. Solva follows up with specific clinical adoption strategy options.
- New devices gathering dust in storage rooms
- Clinicians expressing interest but continuing with old methods
- Low utilisation rates of recently purchased equipment
- Frustration among MedTech developers regarding market penetration
- Inefficient clinical workflows and processes
- Suboptimal resource allocation and equipment underutilisation
- Loss of potential revenue from advanced procedures
- Increased operational costs due to inefficiency and missed savings
- Delayed access to potentially life-saving or improving technologies for patients
- Suboptimal patient outcomes due to reliance on older methods
- Perception as a slow adopter of innovation
- Difficulty attracting top clinical talent seeking modern tools
No verifiable UK data available
Source: No verifiable UK data available
Frequently asked questions
Why does this problem persist?
Clinical behaviour change is the hardest commercial problem in healthcare. Interest does not equal adoption. The gap between a clinician saying 'this looks interesting' and actually changing their practice is where most MedTech commercial strategies fail.
What is the cost of leaving it unaddressed?
No verifiable UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.